Login Register Cart 0
Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Research Article

Real-world Study on the Effect of PARPi as Maintenance Therapy on Platinum Sensitivity after First- and Second-line Chemotherapy in Patients with Recurrent High-grade Serous Epithelial Ovarian Cancer

Author(s): Yanglong Guo, Xi Chen, Xuedong Tang, Shan Pan, Tao Zhu and Yingli Zhang*

Volume 24, Issue 7, 2024

Published on: 01 January, 2024

Page: [733 - 748] Pages: 16

DOI: 10.2174/0115680096271476231226174810

open access plus

conference banner
Abstract

Background: This study investigated the effect of poly(ADP-ribose) polymerase inhibitors (PARPi) as maintenance therapy after first- and second-line chemotherapy on platinum sensitivity in patients with recurrent high-grade serous epithelial ovarian cancer (rHGSOC).

Methods: This study retrospectively analyzed 172 patients with rHGSOC treated at Zhejiang Cancer Hospital and Jiaxing Maternity and Child Health Care Hospital between January 2017 and December 2021. The 1st-PARPi group comprised patients who received a PARPi as maintenance therapy after first-line chemotherapy (n=23), and the 1st-control group comprised those who did not (n = 105). Similarly, the 2nd-PARPi group comprised patients not given a PARPi in their first-line treatment (n = 30), and the 2nd-control group comprised those who were given a PARPi (n = 89).

Results: Among the 23 patients in the 1st-PARPi group and the 105 patients in the 1st-control group, nine and 99 were platinum-sensitive, and 14 and six were platinum-resistant, respectively (hazard ratio [HR]: 14.46, P < 0.0001). Among the 30 patients in the 2nd-PARPi group and 89 patients in the 2nd-control group, 10 and 71 were platinum-sensitive, and 20 and 18 were platinumresistant, respectively (HR: 4.37, P < 0.0001). Age, stage, residual tumor, the courses of platinumbased chemotherapy, and breast cancer susceptibility gene mutations were not associated with platinum sensitivity when using a PARPi as maintenance therapy after first- and second-line chemotherapy.

Conclusion: Patients with rHGSOC using a PARPi were more likely to be platinum-sensitive and develop platinum resistance independent of PARPi duration. Care should be taken when using a PARPi as maintenance therapy after first- and second-line chemotherapy.

Keywords: High-grade serous epithelial ovarian cancer, PARP inhibitor, platinum resistance, platinum-sensitive, residual tumor, BRCA status.

« Previous Next »
Graphical Abstract

[1]
Matulonis, U.A.; Oza, A.M.; Ho, T.W.; Ledermann, J.A. Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials. Cancer, 2015, 121(11), 1737-1746.
[http://dx.doi.org/10.1002/cncr.29082] [PMID: 25336142]
[2]
Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[3]
Foster, J.M.; Zhang, C.; Rehman, S.; Sharma, P.; Alexander, H.R. The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future. CA Cancer J. Clin., 2023, 73(1), 49-71.
[http://dx.doi.org/10.3322/caac.21749] [PMID: 35969103]
[4]
Ledermann, J.; Harter, P.; Gourley, C.; Friedlander, M.; Vergote, I.; Rustin, G.; Scott, C.; Meier, W.; Shapira-Frommer, R.; Safra, T.; Matei, D.; Macpherson, E.; Watkins, C.; Carmichael, J.; Matulonis, U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med., 2012, 366(15), 1382-1392.
[http://dx.doi.org/10.1056/NEJMoa1105535] [PMID: 22452356]
[5]
Ledermann, J.A.; Raja, F.A.; Fotopoulou, C.; Gonzalez-Martin, A.; Colombo, N.; Sessa, C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2013, 24(S6), vi24-vi32.
[http://dx.doi.org/10.1093/annonc/mdt333] [PMID: 24078660]
[6]
Ledermann, J.; Harter, P.; Gourley, C.; Friedlander, M.; Vergote, I.; Rustin, G.; Scott, C.L.; Meier, W.; Shapira-Frommer, R.; Safra, T.; Matei, D.; Fielding, A.; Spencer, S.; Dougherty, B.; Orr, M.; Hodgson, D.; Barrett, J.C.; Matulonis, U. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol., 2014, 15(8), 852-861.
[http://dx.doi.org/10.1016/S1470-2045(14)70228-1] [PMID: 24882434]
[7]
Ledermann, J.; Harter, P.; Gourley, C. Correction to Lancet Oncol 2014; 15: 856. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol., 2015, 16(4), e158.
[PMID: 25846095]
[8]
Colombo, N.; Sessa, C.; du Bois, A.; Ledermann, J.; McCluggage, W.G.; McNeish, I.; Morice, P.; Pignata, S.; Ray-Coquard, I.; Vergote, I.; Baert, T.; Belaroussi, I.; Dashora, A.; Olbrecht, S.; Planchamp, F.; Querleu, D.; Baert, T.; Banerjee, S.; Belaroussi, I.; Blecharz, P.; Bruchim, I.; Cibula, D.; Colombo, N.; Concin, N.; Davidson, B.; Dashora, A.; Devouassoux-Shisheboran, M.; du Bois, A.; Ferrero, A.; Glasspool, R.; González-Martin, A.; Heinzelmann-Schwarz, V.; Joly, F.; Kim, J.W.; Kridelka, F.; Ledermann, J.; Lorusso, D.; Mahner, S.; McCluggage, W.G.; McNeish, I.; Mikami, M.; Mirza, M.R.; Morice, P.; Nicum, S.; Olbrecht, S.; O’Donnell, D.M.; Pautier, P.; Planchamp, F.; Pignata, S.; Querleu, D.; Ray-Coquard, I.; Rodolakis, A.; Sehouli, J.; Selcukbiricik, F.; Sessa, C.; Singh, N.; Tan, D.S.P.; Timmerman, D.; Tognon, G.; van der Velden, J.; Vergote, I.; Witteveen, P.O.; Zeimet, A.G. ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann. Oncol., 2019, 30(5), 672-705.
[http://dx.doi.org/10.1093/annonc/mdz062] [PMID: 31046081]
[9]
Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin., 2022, 72(1), 7-33.
[http://dx.doi.org/10.3322/caac.21708] [PMID: 35020204]
[10]
Osman, M.A.; Elkady, M.S.; Nasr, K.E. Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: A phase III study. Clin. Med. Insights Oncol., 2016, 10, CMO.S38204.
[http://dx.doi.org/10.4137/CMO.S38204] [PMID: 27147900]
[11]
Tomao, F.; D’Incalci, M.; Biagioli, E.; Peccatori, F.A.; Colombo, N. Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum‐free interval: Myth or reality? Cancer, 2017, 123(18), 3450-3459.
[http://dx.doi.org/10.1002/cncr.30830] [PMID: 28678350]
[12]
You, B.; Van Wagensveld, L.; Tod, M.; Sonke, G.S.; Horlings, H.M.; Kruitwagen, R.F.P.M.; Du Bois, A.; Selle, F.; Perren, T.; Pfisterer, J.; Joly, F.; Cook, A.; Kaminsky, M.C.; Wollschlaeger, K.; Lortholary, A.; Tome, O.; Leary, A.; Freyer, G.; Van Der Aa, M.; Colomban, O. Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era. Br. J. Cancer, 2022, 127(1), 79-83.
[http://dx.doi.org/10.1038/s41416-022-01732-7] [PMID: 35361918]
[13]
Pignata, S Treatment of recurrent ovarian cancer. Ann Oncol., 2017, 28(S8), viii51-viii56.
[14]
Moore, K.; Colombo, N.; Scambia, G.; Kim, B.G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G.S.; Gourley, C.; Banerjee, S.; Oza, A.; González-Martín, A.; Aghajanian, C.; Bradley, W.; Mathews, C.; Liu, J.; Lowe, E.S.; Bloomfield, R.; DiSilvestro, P. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med., 2018, 379(26), 2495-2505.
[http://dx.doi.org/10.1056/NEJMoa1810858] [PMID: 30345884]
[15]
Noordermeer, S.M.; van Attikum, H. PARP inhibitor resistance: A tug-of-war in BRCA-mutated cells. Trends Cell Biol., 2019, 29(10), 820-834.
[http://dx.doi.org/10.1016/j.tcb.2019.07.008] [PMID: 31421928]
[16]
Hettle, R.; Posnett, J.; Borrill, J. Challenges in economic modeling of anticancer therapies: An example of modeling the survival benefit of olaparib maintenance therapy for patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer. J. Med. Econ., 2015, 18(7), 516-524.
[http://dx.doi.org/10.3111/13696998.2015.1024682] [PMID: 25735651]
[17]
Corrado, G.; Salutari, V.; Palluzzi, E.; Distefano, M.G.; Scambia, G.; Ferrandina, G. Optimizing treatment in recurrent epithelial ovarian cancer. Expert Rev. Anticancer Ther., 2017, 17(12), 1147-1158.
[http://dx.doi.org/10.1080/14737140.2017.1398088] [PMID: 29086618]
[18]
Lee, E.K.; Matulonis, U.A. Emerging drugs for the treatment of ovarian cancer: A focused review of PARP inhibitors. Expert Opin. Emerg. Drugs, 2020, 25(2), 165-188.
[http://dx.doi.org/10.1080/14728214.2020.1773791] [PMID: 32569489]
[19]
Barber, L.J.; Sandhu, S.; Chen, L.; Campbell, J.; Kozarewa, I.; Fenwick, K.; Assiotis, I.; Rodrigues, D.N.; Reis-Filho, J.S.; Moreno, V.; Mateo, J.; Molife, L.R.; De Bono, J.; Kaye, S.; Lord, C.J.; Ashworth, A. Secondary mutations inBRCA2 associated with clinical resistance to a PARP inhibitor. J. Pathol., 2013, 229(3), 422-429.
[http://dx.doi.org/10.1002/path.4140] [PMID: 23165508]
[20]
Patch, A.M.; Christie, E.L.; Etemadmoghadam, D.; Garsed, D.W.; George, J.; Fereday, S.; Nones, K.; Cowin, P.; Alsop, K.; Bailey, P.J.; Kassahn, K.S.; Newell, F.; Quinn, M.C.J.; Kazakoff, S.; Quek, K.; Wilhelm-Benartzi, C.; Curry, E.; Leong, H.S.; Hamilton, A.; Mileshkin, L.; Au-Yeung, G.; Kennedy, C.; Hung, J.; Chiew, Y.E.; Harnett, P.; Friedlander, M.; Quinn, M.; Pyman, J.; Cordner, S.; O’Brien, P.; Leditschke, J.; Young, G.; Strachan, K.; Waring, P.; Azar, W.; Mitchell, C.; Traficante, N.; Hendley, J.; Thorne, H.; Shackleton, M.; Miller, D.K.; Arnau, G.M.; Tothill, R.W.; Holloway, T.P.; Semple, T.; Harliwong, I.; Nourse, C.; Nourbakhsh, E.; Manning, S.; Idrisoglu, S.; Bruxner, T.J.C.; Christ, A.N.; Poudel, B.; Holmes, O.; Anderson, M.; Leonard, C.; Lonie, A.; Hall, N.; Wood, S.; Taylor, D.F.; Xu, Q.; Fink, J.L.; Waddell, N.; Drapkin, R.; Stronach, E.; Gabra, H.; Brown, R.; Jewell, A.; Nagaraj, S.H.; Markham, E.; Wilson, P.J.; Ellul, J.; McNally, O.; Doyle, M.A.; Vedururu, R.; Stewart, C.; Lengyel, E.; Pearson, J.V.; Waddell, N.; deFazio, A.; Grimmond, S.M.; Bowtell, D.D.L. Whole-genome characterization of chemoresistant ovarian cancer. Nature, 2015, 521(7553), 489-494.
[http://dx.doi.org/10.1038/nature14410] [PMID: 26017449]
[21]
George, A.; Kaye, S.; Banerjee, S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat. Rev. Clin. Oncol., 2017, 14(5), 284-296.
[http://dx.doi.org/10.1038/nrclinonc.2016.191] [PMID: 27958297]
[22]
Hodgson, D.R.; Dougherty, B.A.; Lai, Z.; Fielding, A.; Grinsted, L.; Spencer, S.; O’Connor, M.J.; Ho, T.W.; Robertson, J.D.; Lanchbury, J.S.; Timms, K.M.; Gutin, A.; Orr, M.; Jones, H.; Gilks, B.; Womack, C.; Gourley, C.; Ledermann, J.; Barrett, J.C. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. Br. J. Cancer, 2018, 119(11), 1401-1409.
[http://dx.doi.org/10.1038/s41416-018-0274-8] [PMID: 30353044]
[23]
Cecere, S.C.; Giannone, G.; Salutari, V.; Arenare, L.; Lorusso, D.; Ronzino, G.; Lauria, R.; Cormio, G.; Carella, C.; Scollo, P.; Ghizzoni, V.; Raspagliesi, F.; Di Napoli, M.; Mazzoni, E.; Marchetti, C.; Bergamini, A.; Orditura, M.; Valabrega, G.; Scambia, G.; Maltese, G.; De Matteis, E.; Cardalesi, C.; Loizzi, V.; Boccia, S.; Naglieri, E.; Scandurra, G.; Pignata, S. Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome. Gynecol. Oncol., 2020, 156(1), 38-44.
[http://dx.doi.org/10.1016/j.ygyno.2019.10.023] [PMID: 31699415]
[24]
Popova, T.; Manié, E.; Boeva, V.; Battistella, A.; Goundiam, O.; Smith, N.K.; Mueller, C.R.; Raynal, V.; Mariani, O.; Sastre-Garau, X.; Stern, M.H. Ovarian cancers harboring inactivating mutations in CDK12 display a distinct genomic instability pattern characterized by large tandem duplications. Cancer Res., 2016, 76(7), 1882-1891.
[http://dx.doi.org/10.1158/0008-5472.CAN-15-2128] [PMID: 26787835]
[25]
Goode, E.L.; Block, M.S.; Kalli, K.R.; Vierkant, R.A.; Chen, W.; Fogarty, Z.C.; Gentry-Maharaj, A. Tołoczko, A.; Hein, A.; Bouligny, A.L.; Jensen, A.; Osorio, A.; Hartkopf, A.D.; Ryan, A.; Chudecka-Głaz, A.; Magliocco, A.M.; Hartmann, A.; Jung, A.Y.; Gao, B.; Hernandez, B.Y.; Fridley, B.L.; McCauley, B.M.; Kennedy, C.J.; Wang, C.; Karpinskyj, C.; de Sousa, C.B.; Tiezzi, D.G.; Wachter, D.L.; Herpel, E.; Taran, F.A.; Modugno, F.; Nelson, G.; Lubiński, J.; Menkiszak, J.; Alsop, J.; Lester, J.; García-Donas, J.; Nation, J.; Hung, J.; Palacios, J.; Rothstein, J.H.; Kelley, J.L.; de Andrade, J.M.; Robles-Díaz, L.; Intermaggio, M.P.; Widschwendter, M.; Beckmann, M.W.; Ruebner, M.; Jimenez-Linan, M.; Singh, N.; Oszurek, O.; Harnett, P.R.; Rambau, P.F.; Sinn, P.; Wagner, P.; Ghatage, P.; Sharma, R.; Edwards, R.P.; Ness, R.B.; Orsulic, S.; Brucker, S.Y.; Johnatty, S.E.; Longacre, T.A.; Eilber, U.; McGuire, V.; Sieh, W.; Natanzon, Y.; Li, Z.; Whittemore, A.S.; deFazio, A.; Staebler, A.; Karlan, B.Y.; Gilks, B.; Bowtell, D.D.; Høgdall, E.; Candido dos Reis, F.J.; Steed, H.; Campbell, I.G.; Gronwald, J.; Benítez, J.; Koziak, J.M.; Chang-Claude, J.; Moysich, K.B.; Kelemen, L.E.; Cook, L.S.; Goodman, M.T.; García, M.J.; Fasching, P.A.; Kommoss, S.; Deen, S.; Kjaer, S.K.; Menon, U.; Brenton, J.D.; Pharoah, P.D.P.; Chenevix-Trench, G.; Huntsman, D.G.; Winham, S.J.; Köbel, M.; Ramus, S.J. Dose-response association of CD8 + tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol., 2017, 3(12), e173290.
[http://dx.doi.org/10.1001/jamaoncol.2017.3290] [PMID: 29049607]
[26]
Friedlander, M.; Moore, K.N.; Colombo, N.; Scambia, G.; Kim, B.G.; Oaknin, A.; Lisyanskaya, A.; Sonke, G.S.; Gourley, C.; Banerjee, S.; Oza, A.; González-Martín, A.; Aghajanian, C.; Bradley, W.H.; Liu, J.; Mathews, C.; Selle, F.; Lortholary, A.; Lowe, E.S.; Hettle, R.; Flood, E.; Parkhomenko, E.; DiSilvestro, P. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): A randomised, phase 3 trial. Lancet Oncol., 2021, 22(5), 632-642.
[http://dx.doi.org/10.1016/S1470-2045(21)00098-X] [PMID: 33862001]
[27]
Pignata, S.; Oza, A.; Hall, G.; Pardo, B.; Madry, R.; Cibula, D.; Klat, J.; Montes, A.; Glasspool, R.; Colombo, N.; Pete, I.; Herrero Ibáñez, A.; Marín, M.R.; Ilieva, R.; Timcheva, C.; Di Maio, M.; Blakeley, C.; Taylor, R.; Barnicle, A.; Clamp, A. Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial. Gynecol. Oncol., 2023, 172, 121-129.
[http://dx.doi.org/10.1016/j.ygyno.2023.03.019] [PMID: 37030280]
[28]
Banerjee, S.; Moore, K.N.; Colombo, N.; Scambia, G.; Kim, B.G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G.S.; Gourley, C.; Oza, A.; González-Martín, A.; Aghajanian, C.; Bradley, W.H.; Holmes, E.; Lowe, E.S.; DiSilvestro, P. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol., 2021, 22(12), 1721-1731.
[http://dx.doi.org/10.1016/S1470-2045(21)00531-3] [PMID: 34715071]
[29]
Karam, A.; Ledermann, J.A.; Kim, J.W.; Sehouli, J.; Lu, K.; Gourley, C.; Katsumata, N.; Burger, R.A.; Nam, B.H.; Bacon, M.; Ng, C.; Pfisterer, J.; Bekkers, R.L.M.; Casado Herráez, A.; Redondo, A.; Fujiwara, H.; Gleeson, N.; Rosengarten, O.; Scambia, G.; Zhu, J.; Okamoto, A.; Stuart, G.; Ochiai, K. Fifth ovarian cancer consensus conference of the gynecologic cancer InterGroup: First-line interventions. Ann. Oncol., 2017, 28(4), 711-717.
[http://dx.doi.org/10.1093/annonc/mdx011] [PMID: 28327917]
[30]
Ledermann, J.A.; Raja, F.A.; Fotopoulou, C.; Gonzalez-Martin, A.; Colombo, N.; Sessa, C. Corrections to “Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Ann. Oncol., 2018, 29(S4), iv259.
[http://dx.doi.org/10.1093/annonc/mdy157] [PMID: 30285216]
[31]
Matulonis, U.A.; Harter, P.; Gourley, C.; Friedlander, M.; Vergote, I.; Rustin, G.; Scott, C.; Meier, W.; Shapira-Frommer, R.; Safra, T.; Matei, D.; Fielding, A.; Spencer, S.; Parry, D.; Grinsted, L.; Ledermann, J.A. Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and aBRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer, 2016, 122(12), 1844-1852.
[http://dx.doi.org/10.1002/cncr.29995] [PMID: 27062051]
[32]
Lee, C.K.; Lord, S.; Grunewald, T.; Gebski, V.; Hardy-Bessard, A.C.; Sehouli, J.; Woie, K.; Heywood, M.; Schauer, C.; Vergote, I.; Scambia, G.; Ferrero, A.; Harter, P.; Pujade-Lauraine, E.; Friedlander, M. Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial. Gynecol. Oncol., 2015, 136(1), 18-24.
[http://dx.doi.org/10.1016/j.ygyno.2014.09.017] [PMID: 25281492]
[33]
Jennifer, A.; Iptissem, N.; Aurélie, R.; Philippe, K.; Marc, A.J. The place of secondary complete cytoreductive surgery in advanced ovarian cancer. Horm. Mol. Biol. Clin. Investig., 2020, 41(3), 20190030.
[http://dx.doi.org/10.1515/hmbci-2019-0030] [PMID: 31782948]
[34]
Shi, T.; Zhu, J.; Feng, Y.; Tu, D.; Zhang, Y.; Zhang, P.; Jia, H.; Huang, X.; Cai, Y.; Yin, S.; Jiang, R.; Tian, W.; Gao, W.; Liu, J.; Yang, H.; Cheng, X.; Zang, R. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol., 2021, 22(4), 439-449.
[http://dx.doi.org/10.1016/S1470-2045(21)00006-1] [PMID: 33705695]
[35]
Lorusso, D.; Guy, H.; Samyshkin, Y.; Hawkes, C.; Estenson, K.; Coleman, R.L. Feasibility study of a network meta-analysis and unanchored population-adjusted indirect treatment comparison of niraparib, olaparib, and bevacizumab as maintenance therapies in patients with newly diagnosed advanced ovarian cancer. Cancers, 2022, 14(5), 1285.
[http://dx.doi.org/10.3390/cancers14051285] [PMID: 35267593]
[36]
Paik, E.S.; Lee, Y.J.; Lee, J.Y.; Shin, W.; Park, S.Y.; Kim, S.I.; Kim, J.W.; Choi, C.H.; Kim, B.G. Real-world experience of olaparib maintenance in high-grade serous recurrent ovarian cancer patients with BRCA1/2 mutation: A Korean multicenter study. J. Clin. Med., 2019, 8(11), 1920.
[http://dx.doi.org/10.3390/jcm8111920] [PMID: 31717415]
[37]
DiSilvestro, P.; Colombo, N.; Scambia, G.; Kim, B.G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G.S.; Gourley, C.; Banerjee, S.; Oza, A.; González-Martín, A.; Aghajanian, C.A.; Bradley, W.H.; Mathews, C.A.; Liu, J.; Lowe, E.S.; Bloomfield, R.; Moore, K.N. Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: Subgroup analysis findings from the SOLO1 trial. J. Clin. Oncol., 2020, 38(30), 3528-3537.
[http://dx.doi.org/10.1200/JCO.20.00799] [PMID: 32749942]
[38]
Elyashiv, O.; Ledermann, J.; Parmar, G.; Farrelly, L.; Counsell, N.; Feeney, A.; El-Khouly, F.; Macdonald, I.; Neto, A.; Arthur-Darkwa, E.; Burnett, E.; Jayson, G.C.; Mileshkin, L.; Gourley, C.; Nicum, S. ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy. Int. J. Gynecol. Cancer, 2021, 31(1), 134-138.
[http://dx.doi.org/10.1136/ijgc-2020-002073] [PMID: 33097567]
[39]
Rustin, G.J.S.; Vergote, I.; Eisenhauer, E.; Pujade-Lauraine, E.; Quinn, M.; Thigpen, T.; du Bois, A.; Kristensen, G.; Jakobsen, A.; Sagae, S.; Greven, K.; Parmar, M.; Friedlander, M.; Cervantes, A.; Vermorken, J. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int. J. Gynecol. Cancer, 2011, 21(2), 419-423.
[http://dx.doi.org/10.1097/IGC.0b013e3182070f17] [PMID: 21270624]
[40]
Tjokrowidjaja, A.; Lee, C.K.; Friedlander, M.; Gebski, V.; Gladieff, L.; Ledermann, J.; Penson, R.; Oza, A.; Korach, J.; Huzarski, T.; Manso, L.; Pisano, C.; Asher, R.; Lord, S.J.; Kim, S.I.; Lee, J.Y.; Colombo, N.; Park-Simon, T.W.; Fujiwara, K.; Sonke, G.; Vergote, I.; Kim, J.W.; Pujade-Lauraine, E. Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. Eur. J. Cancer, 2020, 139, 59-67.
[http://dx.doi.org/10.1016/j.ejca.2020.08.021] [PMID: 32977221]
[41]
Fujiwara, K.; Fujiwara, H.; Yoshida, H.; Satoh, T.; Yonemori, K.; Nagao, S.; Matsumoto, T.; Kobayashi, H.; Bourgeois, H.; Harter, P.; Mosconi, A.M.; Vazquez, I.P.; Reinthaller, A.; Fujita, T.; Rowe, P.; Pujade-Lauraine, E.; Ray-Coquard, I. Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial. J. Gynecol. Oncol., 2021, 32(5), e82.
[http://dx.doi.org/10.3802/jgo.2021.32.e82] [PMID: 34378365]
[42]
Poveda, A.; Floquet, A.; Ledermann, J.A.; Asher, R.; Penson, R.T.; Oza, A.M.; Korach, J.; Huzarski, T.; Pignata, S.; Friedlander, M.; Baldoni, A.; Park-Simon, T.W.; Tamura, K.; Sonke, G.S.; Lisyanskaya, A.; Kim, J.H.; Filho, E.A.; Milenkova, T.; Lowe, E.S.; Rowe, P.; Vergote, I.; Pujade-Lauraine, E.; Korach, J.; Huzarski, T.; Byrski, T.; Pautier, P.; Friedlander, M.; Harter, P.; Colombo, N.; Pignata, S.; Scambia, G.; Nicoletto, M.; Nussey, F.; Clamp, A.; Penson, R.; Oza, A.; Poveda Velasco, A.; Rodrigues, M.; Lotz, J-P.; Selle, F.; Ray-Coquard, I.; Provencher, D.; Prat Aparicio, A.; Vidal Boixader, L.; Scott, C.; Tamura, K.; Yunokawa, M.; Lisyanskaya, A.; Medioni, J.; Pécuchet, N.; Dubot, C.; De La Motte Rouge, T.; Kaminsky, M-C.; Weber, B.; Lortholary, A.; Parkinson, C.; Ledermann, J.; Williams, S.; Banerjee, S.; Cosin, J.; Hoffman, J.; Penson, R.; Plante, M.; Covens, A.; Sonke, G.; Joly, F.; Floquet, A.; Banerjee, S.; Hirte, H.; Amit, A.; Park-Simon, T-W.; Matsumoto, K.; Tjulandin, S.; Hoon Kim, J.; Gladieff, L.; Sabbatini, R.; O’Malley, D.; Timmins, P.; Kredentser, D.; Laínez Milagro, N.; Barretina Ginesta, M.P.; Tibau Martorell, A.; Gómez De Liaño Lista, A.; Ojeda González, B.; Mileshkin, L.; Mandai, M.; Boere, I.; Ottevanger, P.; Nam, J-H.; Filho, E.; Hamizi, S.; Cognetti, F.; Warshal, D.; Dickson-Michelson, E.; Kamelle, S.; McKenzie, N.; Rodriguez, G.; Armstrong, D.; Chalas, E.; Celano, P.; Behbakht, K.; Davidson, S.; Welch, S.; Helpman, L.; Fishman, A.; Bruchim, I.; Sikorska, M. Słowińska, A.; Rogowski, W.; Bidziński, M.; Śpiewankiewicz, B.; Casado Herraez, A.; Mendiola Fernández, C.; Gropp-Meier, M.; Saito, T.; Takehara, K.; Enomoto, T.; Watari, H.; Choi, C.H.; Kim, B-G.; Weon Kim, J.; Hegg, R.; Vergote, I. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol., 2021, 22(5), 620-631.
[http://dx.doi.org/10.1016/S1470-2045(21)00073-5] [PMID: 33743851]
[43]
Lee, Y.J.; Lim, M.C.; Kim, B.G.; Ngoi, N.Y.L.; Choi, C.H.; Park, S.Y.; Tan, D.S.P.; Go, Y.; Lee, J.Y. A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01). J. Gynecol. Oncol., 2021, 32(2), e31.
[http://dx.doi.org/10.3802/jgo.2021.32.e31] [PMID: 33559413]
[44]
Kim, Y.N.; Park, B.; Kim, J.W.; Kim, B.G.; Kim, S.W.; Kim, H.S.; Choi, C.H.; Lim, M.C.; YL Ngoi, N.; SP Tan, D.; Lee, J.Y. Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: The multicenter, single-arm phase II study OPEB-01/APGOT-OV4. Nat. Commun., 2023, 14(1), 5476.
[http://dx.doi.org/10.1038/s41467-023-40829-2] [PMID: 37673858]
[45]
Ray-Coquard, I.; Leary, A.; Pignata, S.; Cropet, C.; González-Martín, A.; Marth, C.; Nagao, S.; Vergote, I.; Colombo, N.; Mäenpää, J.; Selle, F.; Sehouli, J.; Lorusso, D.; Guerra Alia, E.M.; Bogner, G.; Yoshida, H.; Lefeuvre-Plesse, C.; Buderath, P.; Mosconi, A.M.; Lortholary, A.; Burges, A.; Medioni, J.; El-Balat, A.; Rodrigues, M.; Park-Simon, T.W.; Dubot, C.; Denschlag, D.; You, B.; Pujade-Lauraine, E.; Harter, P. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: Final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann. Oncol., 2023, 34(8), 681-692.
[http://dx.doi.org/10.1016/j.annonc.2023.05.005] [PMID: 37211045]
[46]
Kondrashova, O.; Nguyen, M.; Shield-Artin, K.; Tinker, A.V.; Teng, N.N.H.; Harrell, M.I.; Kuiper, M.J.; Ho, G.Y.; Barker, H.; Jasin, M.; Prakash, R.; Kass, E.M.; Sullivan, M.R.; Brunette, G.J.; Bernstein, K.A.; Coleman, R.L.; Floquet, A.; Friedlander, M.; Kichenadasse, G.; O’Malley, D.M.; Oza, A.; Sun, J.; Robillard, L.; Maloney, L.; Bowtell, D.; Giordano, H.; Wakefield, M.J.; Kaufmann, S.H.; Simmons, A.D.; Harding, T.C.; Raponi, M.; McNeish, I.A.; Swisher, E.M.; Lin, K.K.; Scott, C.L. Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov., 2017, 7(9), 984-998.
[http://dx.doi.org/10.1158/2159-8290.CD-17-0419] [PMID: 28588062]
[47]
Kristeleit, R.; Lisyanskaya, A.; Fedenko, A.; Dvorkin, M.; de Melo, A.C.; Shparyk, Y.; Rakhmatullina, I.; Bondarenko, I.; Colombo, N.; Svintsitskiy, V.; Biela, L.; Nechaeva, M.; Lorusso, D.; Scambia, G.; Cibula, D.; Póka, R.; Oaknin, A.; Safra, T.; Mackowiak-Matejczyk, B.; Ma, L.; Thomas, D.; Lin, K.K.; McLachlan, K.; Goble, S.; Oza, A.M. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): An international, open-label, randomised, phase 3 trial. Lancet Oncol., 2022, 23(4), 465-478.
[http://dx.doi.org/10.1016/S1470-2045(22)00122-X] [PMID: 35298906]
[48]
Bajrami, I.; Frankum, J.R.; Konde, A.; Miller, R.E.; Rehman, F.L.; Brough, R.; Campbell, J.; Sims, D.; Rafiq, R.; Hooper, S.; Chen, L.; Kozarewa, I.; Assiotis, I.; Fenwick, K.; Natrajan, R.; Lord, C.J.; Ashworth, A. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res., 2014, 74(1), 287-297.
[http://dx.doi.org/10.1158/0008-5472.CAN-13-2541] [PMID: 24240700]
[49]
Bourien, H.; Lefevre, L.B.; Mouret-Reynier, M.A.; Asselain, B.; Lucas, B.; Gavoille, C.; Cornila, C.; Gavoille, L.; Colomba, E.; Patsouris, A.; Fabbro, M.; Chakiba, C.; Toussaint, P.; Simon, H.; Berton, D.; Garbay, D.; Tixidre, C.G.; Coeffic, D.; Morvan, A.; Collard, O.; De La Motte, R.T. Real-world data on olaparib in relapsed BRCA-mutated ovarian cancer: A multicenter GINECO RETROLA cohort study. Anticancer Res., 2023, 43(2), 653-662.
[http://dx.doi.org/10.21873/anticanres.16202] [PMID: 36697069]
[50]
Ramus, S.J.; Song, H.; Dicks, E.; Tyrer, J.P.; Rosenthal, A.N.; Intermaggio, M.P.; Fraser, L.; Gentry-Maharaj, A.; Hayward, J.; Philpott, S.; Anderson, C.; Edlund, C.K.; Conti, D.; Harrington, P.; Barrowdale, D.; Bowtell, D.D.; Alsop, K.; Mitchell, G.; Cicek, M.S.; Cunningham, J.M.; Fridley, B.L.; Alsop, J.; Jimenez-Linan, M.; Poblete, S.; Lele, S.; Sucheston-Campbell, L.; Moysich, K.B.; Sieh, W.; McGuire, V.; Lester, J.; Bogdanova, N.; Dürst, M.; Hillemanns, P.; Odunsi, K.; Whittemore, A.S.; Karlan, B.Y.; Dörk, T.; Goode, E.L.; Menon, U.; Jacobs, I.J.; Antoniou, A.C.; Pharoah, P.D.P.; Gayther, S.A. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. J. Natl. Cancer Inst., 2015, 107(11), djv214.
[http://dx.doi.org/10.1093/jnci/djv214] [PMID: 26315354]
[51]
Zhong, L.; Tran, A.T.; Tomasino, T.; Nugent, E.; Smith, J.A. Cost-effectiveness of niraparib and olaparib as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer. J. Manag. Care Spec. Pharm., 2018, 24(12), 1219-1228.
[http://dx.doi.org/10.18553/jmcp.2018.24.12.1219] [PMID: 30479195]
[52]
Cheng, L.J.; Wong, G.; Chay, W.Y.; Ngeow, J.; Tan, Y.; Soon, S.S.; Aziz, M.I.A.; Pearce, F.; Ng, K. Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer. Expert Rev. Pharmacoecon. Outcomes Res., 2021, 21(3), 441-448.
[http://dx.doi.org/10.1080/14737167.2021.1890587] [PMID: 33593205]
[53]
Leung, J.H.; Lang, H.C.; Wang, S.Y.; Lo, H.F.; Chan, A.L.F. Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer. Expert Rev. Pharmacoecon. Outcomes Res., 2022, 22(3), 489-496.
[http://dx.doi.org/10.1080/14737167.2021.1954506] [PMID: 34241562]
[54]
Qiu, Y.; Zha, J.; Ma, A.; Zhou, T. Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer. Gynecol. Oncol., 2023, 174, 175-181.
[http://dx.doi.org/10.1016/j.ygyno.2023.05.010] [PMID: 37209503]
[55]
Colombo, N.; Moore, K.; Scambia, G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G.S.; Gourley, C.; Banerjee, S.; Oza, A.; González-Martín, A.; Aghajanian, C.; Bradley, W.H.; Kim, J.W.; Mathews, C.; Liu, J.; Lowe, E.S.; Bloomfield, R.; DiSilvestro, P. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. Gynecol. Oncol., 2021, 163(1), 41-49.
[http://dx.doi.org/10.1016/j.ygyno.2021.07.016] [PMID: 34353615]
[56]
Wu, L.; Zhu, J.; Yin, R.; Wu, X.; Lou, G.; Wang, J.; Gao, Y.; Kong, B.; Lu, X.; Zhou, Q.; Wang, Y.; Chen, Y.; Lu, W.; Li, W.; Cheng, Y.; Liu, J.; Ma, X.; Zhang, J. Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort. Gynecol. Oncol., 2021, 160(1), 175-181.
[http://dx.doi.org/10.1016/j.ygyno.2020.10.005] [PMID: 33250205]
[57]
González-Martín, A.; Desauw, C.; Heitz, F.; Cropet, C.; Gargiulo, P.; Berger, R.; Ochi, H.; Vergote, I.; Colombo, N.; Mirza, M.R.; Tazi, Y.; Canzler, U.; Zamagni, C.; Guerra-Alia, E.M.; Levaché, C.B.; Marmé, F.; Bazan, F.; de Gregorio, N.; Dohollou, N.; Fasching, P.A.; Scambia, G.; Rubio-Pérez, M.J.; Milenkova, T.; Costan, C.; Pautier, P.; Ray-Coquard, I. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial. Eur. J. Cancer, 2022, 174, 221-231.
[http://dx.doi.org/10.1016/j.ejca.2022.07.022] [PMID: 36067615]
[58]
Poveda, A.; Lheureux, S.; Colombo, N.; Cibula, D.; Lindemann, K.; Weberpals, J.; Bjurberg, M.; Oaknin, A.; Sikorska, M.; González-Martín, A.; Madry, R.; Pérez, M.J.R.; Ledermann, J.; Davidson, R.; Blakeley, C.; Bennett, J.; Barnicle, A.; Škof, E. Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis. Gynecol. Oncol., 2022, 164(3), 498-504.
[http://dx.doi.org/10.1016/j.ygyno.2021.12.025] [PMID: 35063276]
[59]
Shu, Y.; Liu, Y.; He, X.; Ding, Y.; Zhang, Q. Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china. Front. Pharmacol., 2022, 13, 818579.
[http://dx.doi.org/10.3389/fphar.2022.818579] [PMID: 36034834]
[60]
Asano, F.; Momomura, M.; Morisada, T.; Tsushima, K.; Haruna, Y.; Shibuya, H.; Matsumoto, H.; Kobayashi, Y. Serum CA125 level as predictors of the efficacy of olaparib maintenance therapy for platinum‐sensitive relapsed ovarian cancer. J. Obstet. Gynaecol. Res., 2023, 49(12), 2883-2888.
[http://dx.doi.org/10.1111/jog.15798] [PMID: 37735981]
[61]
DiSilvestro, P.; Banerjee, S.; Colombo, N.; Scambia, G.; Kim, B.G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G.S.; Gourley, C.; Oza, A.; González-Martín, A.; Aghajanian, C.; Bradley, W.; Mathews, C.; Liu, J.; McNamara, J.; Lowe, E.S.; Ah-See, M.L.; Moore, K.N. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1/GOG 3004 trial. J. Clin. Oncol., 2023, 41(3), 609-617.
[http://dx.doi.org/10.1200/JCO.22.01549] [PMID: 36082969]
[62]
Pujade-Lauraine, E.; Ledermann, J.A.; Selle, F.; Gebski, V.; Penson, R.T.; Oza, A.M.; Korach, J.; Huzarski, T.; Poveda, A.; Pignata, S.; Friedlander, M.; Colombo, N.; Harter, P.; Fujiwara, K.; Ray-Coquard, I.; Banerjee, S.; Liu, J.; Lowe, E.S.; Bloomfield, R.; Pautier, P.; Korach, J.; Huzarski, T.; Byrski, T.; Pautier, P.; Friedlander, M.; Harter, P.; Colombo, N.; Pignata, S.; Scambia, G.; Nicoletto, M.; Nussey, F.; Clamp, A.; Penson, R.; Oza, A.; Poveda, V.A.; Rodrigues, M.; Lotz, J-P.; Selle, F.; Ray-Coquard, I.; Provencher, D.; Prat Aparicio, A.; Vidal Boixader, L.; Scott, C.; Tamura, K.; Yunokawa, M.; Lisyanskaya, A.; Medioni, J.; Pécuchet, N.; Dubot, C.; de la Motte, R.T.; Kaminsky, M-C.; Weber, B.; Lortholary, A.; Parkinson, C.; Ledermann, J.; Williams, S.; Banerjee, S.; Cosin, J.; Hoffman, J.; Penson, R.; Plante, M.; Covens, A.; Sonke, G.; Joly, F.; Floquet, A.; Banerjee, S.; Hirte, H.; Amit, A.; Park-Simon, T-W.; Matsumoto, K.; Tjulandin, S.; Kim, J.H.; Gladieff, L.; Sabbatini, R.; O’Malley, D.; Timmins, P.; Kredentser, D.; Laínez Milagro, N.; Barretina Ginesta, M.P.; Tibau Martorell, A.; Gómez de Liaño Lista, A.; Ojeda González, B.; Mileshkin, L.; Mandai, M.; Boere, I.; Ottevanger, P.; Nam, J-H.; Filho, E.; Hamizi, S.; Cognetti, F.; Warshal, D.; Dickson-Michelson, E.; Kamelle, S.; McKenzie, N.; Rodriguez, G.; Armstrong, D.; Chalas, E.; Celano, P.; Behbakht, K.; Davidson, S.; Welch, S.; Helpman, L.; Fishman, A.; Bruchim, I.; Sikorska, M. Słowińska, A.; Rogowski, W.; Bidziński, M.; Śpiewankiewicz, B.; Casado Herraez, A.; Mendiola Fernández, C.; Gropp-Meier, M.; Saito, T.; Takehara, K.; Enomoto, T.; Watari, H.; Choi, C.H.; Kim, B-G.; Kim, J.W.; Hegg, R.; Vergote, I. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol., 2017, 18(9), 1274-1284.
[http://dx.doi.org/10.1016/S1470-2045(17)30469-2] [PMID: 28754483]
[63]
Mirza, M.R.; Monk, B.J.; Herrstedt, J.; Oza, A.M.; Mahner, S.; Redondo, A.; Fabbro, M.; Ledermann, J.A.; Lorusso, D.; Vergote, I.; Ben-Baruch, N.E.; Marth, C. Mądry, R.; Christensen, R.D.; Berek, J.S.; Dørum, A.; Tinker, A.V.; du Bois, A.; González-Martín, A.; Follana, P.; Benigno, B.; Rosenberg, P.; Gilbert, L.; Rimel, B.J.; Buscema, J.; Balser, J.P.; Agarwal, S.; Matulonis, U.A. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med., 2016, 375(22), 2154-2164.
[http://dx.doi.org/10.1056/NEJMoa1611310] [PMID: 27717299]
[64]
Coleman, R.L.; Oza, A.M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J.I.; Clamp, A.; Scambia, G.; Leary, A.; Holloway, R.W.; Gancedo, M.A.; Fong, P.C.; Goh, J.C.; O’Malley, D.M.; Armstrong, D.K.; Garcia-Donas, J.; Swisher, E.M.; Floquet, A.; Konecny, G.E.; McNeish, I.A.; Scott, C.L.; Cameron, T.; Maloney, L.; Isaacson, J.; Goble, S.; Grace, C.; Harding, T.C.; Raponi, M.; Sun, J.; Lin, K.K.; Giordano, H.; Ledermann, J.A.; Buck, M.; Dean, A.; Friedlander, M.L.; Goh, J.C.; Harnett, P.; Kichenadasse, G.; Scott, C.L.; Denys, H.; Dirix, L.; Vergote, I.; Elit, L.; Ghatage, P.; Oza, A.M.; Plante, M.; Provencher, D.; Weberpals, J.I.; Welch, S.; Floquet, A.; Gladieff, L.; Joly, F.; Leary, A.; Lortholary, A.; Lotz, J.; Medioni, J.; Tredan, O.; You, B.; El-Balat, A.; Hänle, C.; Krabisch, P.; Neunhöffer, T.; Pölcher, M.; Wimberger, P.; Amit, A.; Kovel, S.; Leviov, M.; Safra, T.; Shapira-Frommer, R.; Stemmer, S.; Bologna, A.; Colombo, N.; Lorusso, D.; Pignata, S.; Sabbatini, R.F.; Scambia, G.; Tamberi, S.; Zamagni, C.; Fong, P.C.; O’Donnell, A.; Gancedo, M.A.; Herraez, A.C.; Garcia-Donas, J.; Guerra, E.M.; Oaknin, A.; Palacio, I.; Romero, I.; Sanchez, A.; Banerjee, S.N.; Clamp, A.; Drew, Y.; Gabra, H.G.; Jackson, D.; Ledermann, J.A.; McNeish, I.A.; Parkinson, C.; Powell, M.; Aghajanian, C.; Armstrong, D.K.; Birrer, M.J.; Buss, M.K.; Chambers, S.K.; Chen, L.; Coleman, R.L.; Holloway, R.W.; Konecny, G.E.; Ma, L.; Morgan, M.A.; Morris, R.T.; Mutch, D.G.; O’Malley, D.M.; Slomovitz, B.M.; Swisher, E.M.; Vanderkwaak, T.; Vulfovich, M. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2017, 390(10106), 1949-1961.
[http://dx.doi.org/10.1016/S0140-6736(17)32440-6] [PMID: 28916367]
[65]
Ray-Coquard, I.; Pautier, P.; Pignata, S.; Pérol, D.; González-Martín, A.; Berger, R.; Fujiwara, K.; Vergote, I.; Colombo, N.; Mäenpää, J.; Selle, F.; Sehouli, J.; Lorusso, D.; Guerra Alía, E.M.; Reinthaller, A.; Nagao, S.; Lefeuvre-Plesse, C.; Canzler, U.; Scambia, G.; Lortholary, A.; Marmé, F.; Combe, P.; de Gregorio, N.; Rodrigues, M.; Buderath, P.; Dubot, C.; Burges, A.; You, B.; Pujade-Lauraine, E.; Harter, P. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med., 2019, 381(25), 2416-2428.
[http://dx.doi.org/10.1056/NEJMoa1911361] [PMID: 31851799]
[66]
González-Martín, A.; Pothuri, B.; Vergote, I.; DePont Christensen, R.; Graybill, W.; Mirza, M.R.; McCormick, C.; Lorusso, D.; Hoskins, P.; Freyer, G.; Baumann, K.; Jardon, K.; Redondo, A.; Moore, R.G.; Vulsteke, C.; O’Cearbhaill, R.E.; Lund, B.; Backes, F.; Barretina-Ginesta, P.; Haggerty, A.F.; Rubio-Pérez, M.J.; Shahin, M.S.; Mangili, G.; Bradley, W.H.; Bruchim, I.; Sun, K.; Malinowska, I.A.; Li, Y.; Gupta, D.; Monk, B.J. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med., 2019, 381(25), 2391-2402.
[http://dx.doi.org/10.1056/NEJMoa1910962] [PMID: 31562799]
[67]
Coleman, R.L.; Fleming, G.F.; Brady, M.F.; Swisher, E.M.; Steffensen, K.D.; Friedlander, M.; Okamoto, A.; Moore, K.N.; Efrat Ben-Baruch, N.; Werner, T.L.; Cloven, N.G.; Oaknin, A.; DiSilvestro, P.A.; Morgan, M.A.; Nam, J.H.; Leath, C.A., III; Nicum, S.; Hagemann, A.R.; Littell, R.D.; Cella, D.; Baron-Hay, S.; Garcia-Donas, J.; Mizuno, M.; Bell-McGuinn, K.; Sullivan, D.M.; Bach, B.A.; Bhattacharya, S.; Ratajczak, C.K.; Ansell, P.J.; Dinh, M.H.; Aghajanian, C.; Bookman, M.A. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N. Engl. J. Med., 2019, 381(25), 2403-2415.
[http://dx.doi.org/10.1056/NEJMoa1909707] [PMID: 31562800]
[68]
Matulonis, U.A.; Herrstedt, J.; Tinker, A.; Marme, F.; Redondo, A.; Kalbacher, E.; Ledermann, J.A.; Pikiel, J.; Christensen, R.P.; Berek, J.S.; Juhler-Nøttrup, T.; Oza, A.M.; Meier, W.; Gil-Martin, M.; Hardy-Bessard, A-C.; Monk, B.J.; Rosenberg, P.; Wenham, R.M.; Hazard, S.; Mirza, M.R. Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). J. Clin. Oncol., 2017, 35(S15), 5534.
[http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5534]
[69]
Mirza, M.R.; Coleman, R.L.; González-Martín, A.; Moore, K.N.; Colombo, N.; Ray-Coquard, I.; Pignata, S. Corrigendum to ‘The forefront of ovarian cancer therapy: Update on PARP inhibitors’: [Annals of Oncology 31 (2020) 1148-1159]. Ann. Oncol., 2021, 32(8), 1066-1067.
[http://dx.doi.org/10.1016/j.annonc.2021.05.796] [PMID: 34090767]
[70]
Wu, X.H.; Zhu, J.Q.; Yin, R.T.; Yang, J.X.; Liu, J.H.; Wang, J.; Wu, L.Y.; Liu, Z.L.; Gao, Y.N.; Wang, D.B.; Lou, G.; Yang, H.Y.; Zhou, Q.; Kong, B.H.; Huang, Y.; Chen, L.P.; Li, G.L.; An, R.F.; Wang, K.; Zhang, Y.; Yan, X.J.; Lu, X.; Lu, W.G.; Hao, M.; Wang, L.; Cui, H.; Chen, Q.H.; Abulizi, G.; Huang, X.H.; Tian, X.F.; Wen, H.; Zhang, C.; Hou, J.M.; Mirza, M.R. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): A randomized, double-blind, placebo-controlled phase III trial☆. Ann. Oncol., 2021, 32(4), 512-521.
[http://dx.doi.org/10.1016/j.annonc.2020.12.018] [PMID: 33453391]
[71]
Harter, P.; Mouret-Reynier, M.A.; Pignata, S.; Cropet, C.; González-Martín, A.; Bogner, G.; Fujiwara, K.; Vergote, I.; Colombo, N.; Nøttrup, T.J.; Floquet, A.; El-Balat, A.; Scambia, G.; Guerra Alia, E.M.; Fabbro, M.; Schmalfeldt, B.; Hardy-Bessard, A.C.; Runnebaum, I.; Pujade-Lauraine, E.; Ray-Coquard, I. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. Gynecol. Oncol., 2022, 164(2), 254-264.
[http://dx.doi.org/10.1016/j.ygyno.2021.12.016] [PMID: 34952708]
[72]
Park, J.; Lim, M.C.; Lee, J.K.; Jeong, D.H.; Kim, S.I.; Choi, M.C.; Kim, B.G.; Lee, J.Y. A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial. J. Gynecol. Oncol., 2022, 33(2), e12.
[http://dx.doi.org/10.3802/jgo.2022.33.e12] [PMID: 34910393]
[73]
Li, N.; Zhu, J.; Yin, R.; Wang, J.; Pan, L.; Kong, B.; Zheng, H.; Liu, J.; Wu, X.; Wang, L.; Huang, Y.; Wang, K.; Zou, D.; Zhao, H.; Wang, C.; Lu, W.; Lin, A.; Lou, G.; Li, G.; Qu, P.; Yang, H.; Zhang, Y.; Cai, H.; Pan, Y.; Hao, M.; Liu, Z.; Cui, H.; Yang, Y.; Yao, S.; Zhen, X.; Hang, W.; Hou, J.; Wang, J.; Wu, L. Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer. JAMA Oncol., 2023, 9(9), 1230-1237.
[http://dx.doi.org/10.1001/jamaoncol.2023.2283] [PMID: 37440217]
[74]
National Comprehensive Cancer Network. Ovarian Cancer Including Fallopian Tube Cancerand Primary Peritoneal Cancer (Version 1.2023). 2022. Available from: https://wwwnccnorg/login?ReturnURL=https://wwwnccnorg/professionals/physician_gls/pdf/ovarianpdf (Accessed on: December 22, 2022).
[75]
Du Bois, A.; Sehouli, J.; Vergote, I.; Ferron, G.; Reuss, A.; Meier, W.; Greggi, S.; Jensen, P.T.; Selle, F.; Guyon, F.; Pomel, C.; Lecuru, F.; Zang, R.; Avall-Lundqvist, E.; Kim, J-W.; Ponce, J.; Raspagliesi, F.; Ghaem-Maghami, S.; Reinthaller, A.; Harter, P. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20. J. Clin. Oncol., 2020, 38(S15), 6000.
[http://dx.doi.org/10.1200/JCO.2020.38.15_suppl.6000]
[76]
Park, J.; Kim, S.I.; Jeong, S.Y.; Kim, Y.; Bookman, M.A.; Kim, J.W.; Kim, B.G.; Lee, J.Y. Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study. Gynecol. Oncol., 2022, 165(1), 97-104.
[http://dx.doi.org/10.1016/j.ygyno.2022.02.002] [PMID: 35153073]
[77]
Guo, Y.; Zhang, Y. Real world study on the effect of PARPi as maintenance therapy after first-line and second-line chemotherapy on platinum sensitivity in patients with recurrent high-grade serous epithelial ovarian cancer. J. Clin. Oncol., 2023, 41(16)(Suppl.), e17574-e17574.
[http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e17574]

Rights & Permissions Print Cite
Article Metrics
27
1
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy